Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc.verified

SNDX

Price:

$23.321

Market Cap:

$1.98B

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with Nation...[Read more]

Industry

Biotechnology

IPO Date

2016-03-02

Stock Exchange

NASDAQ

Ticker

SNDX

The PE Ratio as of July 2024 (TTM) for Syndax Pharmaceuticals, Inc. (SNDX) is -7.20

According to Syndax Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -7.20. This represents a change of 12.82% compared to the average of -6.38 of the last 4 quarters.

Syndax Pharmaceuticals, Inc. (SNDX) Historical PE Ratio (quarterly & annually)

How has SNDX PE Ratio performed in the past?

The mean historical PE Ratio of Syndax Pharmaceuticals, Inc. over the last ten years is -1.10. The current -7.20 PE Ratio has changed 65.26% with respect to the historical average. Over the past ten years (40 quarters), SNDX's PE Ratio was at its highest in in the December 2021 quarter at 2.95. The PE Ratio was at its lowest in in the June 2014 quarter at -64.78.

Quarterly (TTM)
Annual

Average

-1.10

Median

-5.30

Minimum

-12.57

Maximum

45.72

Syndax Pharmaceuticals, Inc. (SNDX) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Syndax Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 213.42%

Maximum Annual PE Ratio = 45.72

Minimum Annual Increase = -463.66%

Minimum Annual PE Ratio = -12.57

Quarterly (TTM)
Annual
YearPE RatioChange
2023-7.26-32.48%
2022-10.76-123.53%
202145.72-463.66%
2020-12.57162.79%
2019-4.78213.42%
2018-1.53-49.54%
2017-3.0328.34%
2016-2.36-72.73%
2015-8.6448.81%
2014-5.81-14.34%

Syndax Pharmaceuticals, Inc. (SNDX) Average PE Ratio

How has SNDX PE Ratio performed in the past?

The current PE Ratio of Syndax Pharmaceuticals, Inc. (SNDX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

9.23

5-year avg

2.07

10-year avg

-1.10

Syndax Pharmaceuticals, Inc. (SNDX) PE Ratio vs. Peers

How is SNDX’s PE Ratio compared to its peers?

Syndax Pharmaceuticals, Inc.’s PE Ratio is less than Cogent Biosciences, Inc. (-4.11), less than Cullinan Oncology, Inc. (-6.67), less than KalVista Pharmaceuticals, Inc. (-5.06), less than Mersana Therapeutics, Inc. (-1.94), less than Pliant Therapeutics, Inc. (-4.47), greater than Revolution Medicines, Inc. (-15.86), less than Viridian Therapeutics, Inc. (-4.41), less than Inozyme Pharma, Inc. (-4.60), less than Aerovate Therapeutics, Inc. (-0.64), greater than Keros Therapeutics, Inc. (-9.10), less than Mineralys Therapeutics, Inc. (-6.82), less than Replimune Group, Inc. (-2.97), greater than Vaxcyte, Inc. (-21.78), greater than Larimar Therapeutics, Inc. (-11.38), greater than Merus N.V. (-21.34), less than Sutro Biopharma, Inc. (-2.08), greater than Cytokinetics, Incorporated (-11.03), greater than DICE Therapeutics, Inc. (-23.17), greater than Edgewise Therapeutics, Inc. (-17.58), greater than Karuna Therapeutics, Inc. (-29.52), greater than Dyne Therapeutics, Inc. (-13.81),

Build a custom stock screener for Syndax Pharmaceuticals, Inc. (SNDX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Syndax Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Syndax Pharmaceuticals, Inc. (SNDX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Syndax Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Syndax Pharmaceuticals, Inc.'s PE Ratio?

How is the PE Ratio calculated for Syndax Pharmaceuticals, Inc. (SNDX)?

What is the highest PE Ratio for Syndax Pharmaceuticals, Inc. (SNDX)?

What is the 3-year average PE Ratio for Syndax Pharmaceuticals, Inc. (SNDX)?

What is the 5-year average PE Ratio for Syndax Pharmaceuticals, Inc. (SNDX)?

How does the current PE Ratio for Syndax Pharmaceuticals, Inc. (SNDX) compare to its historical average?